• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Instil Bio, Inc. (NQ:TIL)

19.09 -1.09 (-5.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 87,429
Open 20.00
Bid (Size) 18.18 (1)
Ask (Size) 19.30 (1)
Prev. Close 20.17
Today's Range 18.05 - 20.33
52wk Range 10.80 - 44.50
Shares Outstanding 128,761,873
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
September 10, 2025
From Instil Bio
Via GlobeNewswire
Instil Bio Posts Wider Loss in Q2
August 13, 2025
Via The Motley Fool
Topics Intellectual Property

Performance

YTD
-11.7%
-11.7%
1 Month
-17.2%
-17.2%
3 Month
-31.1%
-31.1%
6 Month
+23.5%
+23.5%
1 Year
-53.5%
-53.5%

More News

Read More
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
From Instil Bio
Via GlobeNewswire
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
July 31, 2025
From Instil Bio
Via GlobeNewswire
Here are the top movers in Monday's session.
July 07, 2025
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
July 02, 2025
Via Benzinga
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025
From Instil Bio
Via GlobeNewswire
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
June 11, 2025
From Instil Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
June 02, 2025
Via Benzinga
These stocks are moving in today's after hours session
June 02, 2025
Via Chartmill
These stocks that are showing activity before the opening bell on Monday.
June 02, 2025
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 02, 2025
Via Benzinga
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
June 02, 2025
From Instil Bio
Via GlobeNewswire
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
May 30, 2025
From Instil Bio
Via GlobeNewswire
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
May 23, 2025
From Instil Bio
Via GlobeNewswire
Keep an eye on the top gainers and losers in Thursday's session.
May 22, 2025
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
May 22, 2025
Via Benzinga
These stocks are moving in today's session
May 22, 2025
Via Chartmill
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated
May 22, 2025
From Instil Bio
Via GlobeNewswire
What's going on in today's pre-market session
May 20, 2025
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 20, 2025
Via Benzinga
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
May 20, 2025
Via Benzinga
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025
From Instil Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
April 25, 2025
Via Benzinga
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 04, 2025
From Instil Bio
Via GlobeNewswire

Frequently Asked Questions

Is Instil Bio, Inc. publicly traded?
Yes, Instil Bio, Inc. is publicly traded.
What exchange does Instil Bio, Inc. trade on?
Instil Bio, Inc. trades on the Nasdaq Stock Market
What is the ticker symbol for Instil Bio, Inc.?
The ticker symbol for Instil Bio, Inc. is TIL on the Nasdaq Stock Market
What is the current price of Instil Bio, Inc.?
The current price of Instil Bio, Inc. is 19.09
When was Instil Bio, Inc. last traded?
The last trade of Instil Bio, Inc. was at 10/17/25 04:00 PM ET
What is the market capitalization of Instil Bio, Inc.?
The market capitalization of Instil Bio, Inc. is 2.46B
How many shares of Instil Bio, Inc. are outstanding?
Instil Bio, Inc. has 2B shares outstanding.
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap